Evaluation of Gadoterate in Patients With Decreased Kidney Function

Gadolinium-based intravenous contrast agents are widely used for the enhancement of MRI
findings. However, these agents have been implicated in varying degrees of nephrotoxicity and
therefore are not usually used in patients with renal dysfunction. Gadoterate is a Gadolinium
agent and previous studies have indicated that it is safe in patients with decreased kidney
function. The purpose of this study is to evaluate the safety and efficacy of using
Gadoterate in this patient population.

Participants who have been scheduled for an MRI will choose to either receive Gadoterate
contrast as part of their MRI or not receive Gadoterate as part of their MRI.

Inclusion Criteria:

- Glomerular filtration rates (GFR) less than 30 ml/min but not on dialysis

- Being sent for an MRI examination in the course of routine clinical evaluation of one
of the following indications: suspected or known head/neck/brain mass, hepatic mass,
renal mass, pancreatic mass, or prostate mass, as well as evaluation of carotid or
abdominopelvic vasculature.

Exclusion Criteria:

- Pregnant and lactating females

- Planned initiation of chemotherapy or surgery within 72 hours of the MRI exam

- Hemodynamic instability or acute coronary syndrome

- History of nephrotoxic medication within 2 weeks of the exam

- Less than 18 years old